Cargando…

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

Small cell lung cancer (SCLC) is an aggressive type of lung cancer with high mortality that is caused by frequent relapses and acquired resistance. Despite that several target-based approaches with potential therapeutic impact on SCLC have been identified, numerous targeted drugs have not been succe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fiorentino, Francesco Paolo, Marchesi, Irene, Schröder, Christoph, Schmidt, Ronny, Yokota, Jun, Bagella, Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766292/ https://www.ncbi.nlm.nih.gov/pubmed/33339368 http://dx.doi.org/10.3390/ijms21249595

Ejemplares similares

The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine
por: Xie, Fang, et al.
Publicado: (2018)

Retraction Note: The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine
por: Xie, Fang, et al.
Publicado: (2023)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021)

BET inhibitors: Betting on improved outcomes in uterine serous carcinoma
por: Zeybek, Burak, et al.
Publicado: (2018)

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer
por: Lui, Goldie Y.L., et al.
Publicado: (2020)

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
por: Ding, Xia, et al.
Publicado: (2022)

BET in Pulmonary Arterial Hypertension: Exploration of BET Inhibitors to Reverse Vascular Remodeling
por: Dai, Zhiyu, et al.
Publicado: (2019)

MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells
por: Kato, Fuyumi, et al.
Publicado: (2016)

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib
por: Li, Jiaguo, et al.
Publicado: (2020)

The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53
por: Yi, Joanna S., et al.
Publicado: (2021)

Design and Characterization of Bivalent BET Inhibitors
por: Tanaka, Minoru, et al.
Publicado: (2016)

To Bet or Not to Bet on T-bet As a Therapeutic Target in Emphysema?
por: Wang, Xiaoyun, et al.
Publicado: (2019)

Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells
por: Kang, Sun Kyoung, et al.
Publicado: (2020)

Retraction Note: BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
por: Yao, Zhicheng, et al.
Publicado: (2022)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
por: Engert, Florian, et al.
Publicado: (2016)

How Much Can We Bet on Activity of BET Inhibitors Beyond NUT–Midline Carcinoma?
por: Martin-Romano, Patricia, et al.
Publicado: (2019)

BET-inhibitors as sensitizers for BH3-mimetics
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

The emerging role of BET inhibitors in breast cancer
por: Andrikopoulou, A., et al.
Publicado: (2020)

The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression
por: Deng, Manman, et al.
Publicado: (2023)

The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors
por: Miller, Aubrey L., et al.
Publicado: (2019)

Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers
por: Juan, Alberto, et al.
Publicado: (2022)

Intrinsic BET inhibitor resistance in prostate cancer caused by SPOP mutation-mediated BET protein stabilization
por: Zhang, Pingzhao, et al.
Publicado: (2017)

Opposing effects of cancer type-specific SPOP mutations on BET protein degradation and sensitivity to BET inhibitors
por: Janouskova, Hana, et al.
Publicado: (2017)

BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice
por: Korb, Erica, et al.
Publicado: (2015)

Lifetime Prediction of Polymers: To Bet, or Not to Bet—Is This the Question?
por: Blanco, Ignazio
Publicado: (2018)

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
por: Herriott, Ashleigh, et al.
Publicado: (2015)

Modulation of Virulence-Associated Traits in Aspergillus fumigatus by BET Inhibitor JQ1
por: Orekhova, Anastasia, et al.
Publicado: (2022)

When are the BET factors the most sensitive to bromodomain inhibitors?
por: Khochbin, Saadi
Publicado: (2013)

BET bromodomain inhibitor (JQ1) and tumor angiogenesis
por: Bid, Hemant Kumar, et al.
Publicado: (2016)

BET inhibitors as novel therapeutic agents in breast cancer
por: Ocaña, Alberto, et al.
Publicado: (2017)

Chemical probes and inhibitors of bromodomains outside the BET family
por: Moustakim, Moses, et al.
Publicado: (2016)

Role of BET Inhibitors in Triple Negative Breast Cancers
por: Khandekar, Durga, et al.
Publicado: (2020)

Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers
por: Lakomy, David S., et al.
Publicado: (2019)

Bromodomain Inhibitor JQ1 Provides Novel Insights and Perspectives in Rhabdomyosarcoma Treatment
por: Marchesi, Irene, et al.
Publicado: (2022)

Catching BETs by viruses
por: Zandian, Mohamad, et al.
Publicado: (2022)

Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells
por: Borbely, Gabor, et al.
Publicado: (2015)

BET inhibitors enhance embryonic and fetal globin expression in erythroleukemia cell lines
por: Cao, John Z., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jk7bvtmapb3d2p2183q7u30gm1